Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 8 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus MIDAZOLAM IN 0 8 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs MIDAZOLAM IN 0.8% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) type A receptor activity, resulting in increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
IV: 0.5-2 mg every 2-5 minutes as needed for procedural sedation. IM: 2-5 mg 30-60 minutes before procedure.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life: 1.8-6.4 hours (mean 3.1 h) in healthy adults; prolonged in elderly (5-6 h), obesity, hepatic impairment (up to 13 h), and critical illness (up to 20+ h).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal (approx. 45-57% as glucuronide conjugates; <1% unchanged); biliary/fecal (approx. 2-10%)
Category C
Category A/B
Electrolyte
Electrolyte